Gland Pharma Q1FY27 Revenue Up 20% YoY to ₹18,003 Mn

Gland Pharma Limited announced its financial results for the first quarter ended June 30th, 2026, reporting record revenues of ₹18,003 million, a 20% increase year-on-year. Profit After Tax (PAT) surged by 47% year-on-year to ₹3,170 million. The company highlighted strong execution of its CDMO strategy and resilience in its B2B business model, with both segments contributing 50% of revenues and showing significant growth. CDMO revenue grew by 20% YoY, while B2B revenue increased by 19% YoY. Adjusted EBITDA also saw a substantial rise of 37% YoY to ₹5,102 million, with an improved margin of 28%. The company continues to invest in differentiated technologies and capacity expansions to support sustainable long-term growth.